Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK in Refractory Metastatic Colorectal Cancer
NCT05213195Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Dec 2021
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR-NK in colorectal cancer (CRC), sponsored by Zhejiang University. Primary endpoints: Dose-Limiting Toxicity at 28 days and Maximal Tolerable Dose at 28 days. Started Dec 2021; status: recruiting.
02
Drugs
NKG2D CAR-NK
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05213195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05213195.